Guard Therapeutics Q4: Exciting Times Ahead

Research Note

2021-02-24

11:49

Redeye notes that the Q4 report from Guard did not include any surprises. We provide a brief comment on the financials and highlight the most important events during the period. We continue to see a good case in Guard and reiterate our Base case of SEK 3 per share.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.